Quick Answer
LB PHARMACEUTICALS INC reported Net Income of -$25.20 million for fiscal year 2025.
LB PHARMACEUTICALS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net Income | -$25.20M +60.1% |
-$63.10M | — |
| Diluted EPS | -$3.13 +98.2% |
-$176.15 | — |
| Total Assets | $312.93M +833.2% |
$33.53M | — |
| Cash and Equivalents | $250.17M +988.8% |
$22.98M | — |
| Stockholders Equity | $301.31M +418.7% |
-$94.55M -174.3% |
-$34.47M |
| R&D Expense | $16.74M -67.3% |
$51.17M | — |
| Shares Outstanding | 25.30M +9953.2% |
251,655 | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$3.56M | +74.9% | +27.0% |
| Diluted EPS | September 30, 2025 | -$0.61 | +98.5% | +98.5% |
| Total Assets | September 30, 2025 | $320.75M | — | +856.5% |
| Cash and Equivalents | September 30, 2025 | $269.74M | — | +1073.9% |
| Stockholders Equity | September 30, 2025 | $310.22M | +439.2% | +398.7% |
| R&D Expense | September 30, 2025 | $2.42M | -77.3% | -77.3% |
| Shares Outstanding | September 30, 2025 | 25.30M | — | +9953.1% |
- LB PHARMACEUTICALS INC reported Net Income of -$25.20 million for fiscal year 2025.
- LB PHARMACEUTICALS INC showed an increase of +60.1% in Net Income compared to the prior fiscal year.
- LB PHARMACEUTICALS INC reported Diluted EPS of $3.13 per share (loss) for fiscal year 2025.
- LB PHARMACEUTICALS INC showed an increase of +98.2% in Diluted EPS compared to the prior fiscal year.
- LB PHARMACEUTICALS INC reported Total Assets of $312.93 million for fiscal year 2025.
- LB PHARMACEUTICALS INC showed an increase of +833.2% in Total Assets compared to the prior fiscal year.
- LB PHARMACEUTICALS INC reported Cash and Equivalents of $250.17 million for fiscal year 2025.
- LB PHARMACEUTICALS INC showed an increase of +988.8% in Cash and Equivalents compared to the prior fiscal year.
- LB PHARMACEUTICALS INC reported Stockholders Equity of $301.31 million for fiscal year 2025.
- LB PHARMACEUTICALS INC showed an increase of +418.7% in Stockholders Equity compared to the prior fiscal year.
- LB PHARMACEUTICALS INC reported R&D Expense of $16.74 million for fiscal year 2025.
- LB PHARMACEUTICALS INC showed a decrease of -67.3% in R&D Expense compared to the prior fiscal year.
- LB PHARMACEUTICALS INC reported Shares Outstanding of 25.30 million shares for fiscal year 2025.
- LB PHARMACEUTICALS INC showed an increase of +9953.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: